Prelude Therapeutics Incorporated
Symbol: PRLD (NASDAQ)
1.22
▲ (2.52%) 0.030
Company Description:
Prelude Therapeutics Incorp is a clinical stage precision oncology company focused on discovering and developing small molecule therapies optimized to target the key driver mechanisms in cancers with high unmet needs. The company's pipeline includes four candidates currently in clinical development: PRT1419, a potent, selective inhibitor of MCL1; PRT2527, a potent and selective CDK9 inhibitor, PRT3645, a next-generation CDK4/6 inhibitor, and PRT3789 a first-in-class SMARCA2/BRM protein degrader.
Key Stats
- Today's Open: $1.2
- Today's High: $1.25
- Today's Low: $1.143
- Today's Volume: 162.76K
- Yesterday Close: $1.19
- Yesterday High: $1.25
- Yesterday Low: $1.17
- Yesterday Volume: 109.60K
- Last Min Volume: 2
- Last Min High: $1.22
- Last Min Low: $1.22
- Last Min VWAP: $1.22
Company Profile
- Name: Prelude Therapeutics Incorporated
- Website: https://www.preludetx.com
- Listed Date: 2020-09-25
- Location: WILMINGTON, DE
- Market Status: Active
- CIK Number: 0001678660
- SIC Code: 2834
- SIC description: PHARMACEUTICAL PREPARATIONS
- Market Cap: $67.35M
- Round Lot: 100
- Outstanding Shares: 56.60M
- Asset Type: CS
RECENT FILINGS FOR PRLD
| Filing Date | Filing Type | Format |
|---|---|---|
| 2025-08-14 | 10-Q | View |
| 2025-08-14 | 8-K | View |
| 2025-07-08 | 4 | View |
| 2025-06-13 | SCHEDULE 13D/A | View |
| 2025-06-13 | 4 | View |
| 2025-06-13 | 3 | View |
| 2025-06-13 | 4 | View |
| 2025-06-13 | 4 | View |
| 2025-06-13 | 4 | View |
| 2025-06-13 | 4 | View |
| 2025-06-13 | 4 | View |
| 2025-06-13 | 8-K | View |
| 2025-05-15 | SCHEDULE 13G/A | View |
| 2025-05-06 | 10-Q | View |
| 2025-05-06 | 8-K | View |
| 2025-04-29 | ARS | View |
| 2025-04-29 | DEFA14A | View |
| 2025-04-29 | DEF 14A | View |
| 2025-04-25 | 8-K | View |
| 2025-04-11 | PRE 14A | View |
Latest News on PRLD